文献速递肝病胰腺与胆道疾病消化道肿瘤与早癌

系统治疗整合至肝癌早期阶段的综述

Integrating systemic therapy in the earlier stages of liver cancer.
PubMed 文献 · J Hepatol · 2026-07-02

本综述讨论在肝癌早期阶段整合局部与系统治疗的试验设计挑战及可用的终点指标,并汇总肝细胞癌经动脉与系统治疗联合、辅助与新辅助系统治疗的数据,以及胆道癌辅助与新辅助治疗的最新进展。虽然各场景均有 promising 数据,但这些策略能否成为未来标准治疗仍不确定。

要点

  • 肝细胞癌免疫治疗已改善生存与生活质量
  • 胆道癌免疫治疗获益有限,分子靶向治疗在特定分子改变人群影响显著
  • 早期阶段联合局部与系统治疗的试验设计及终点选择仍存挑战

核心结论

  • 在肝癌早期阶段整合系统治疗虽有 promising 数据,但能否成为标准治疗仍不确定。

研究设计与样本

  • 综述,讨论早期阶段联合局部与系统治疗的试验设计挑战及不同终点指标。

主要发现

  • 肝细胞癌中免疫治疗改善生存与生活质量。
  • 胆道癌中免疫治疗显示 modest 获益,分子靶向治疗在特定分子改变人群影响显著。
  • 综述汇总了肝细胞癌经动脉与系统治疗联合、辅助与新辅助系统治疗的数据。
  • 综述回顾了胆道癌辅助与新辅助治疗的最新进展。

局限性

  • 这些策略能否在今后几年成为标准治疗仍存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of advanced primary liver cancer has seen major improvement in recent years. In hepatocellular carcinoma (HCC), immunotherapy has improved both survival and quality of life. In biliary tract cancers (BTC), immunotherapy has shown modest benefits, while molecular targeted therapies have had a major impact in selected populations defined by molecular alterations. These advances are now being tested at earlier disease stages. In this review, we first discuss the challenges in designing trials that combine local and systemic treatment at earlier stages, and the different endpoints that might be used. We then present the available data on the combination of intra-arterial and systemic treatments in HCC. We continue with a discussion of the available data on adjuvant and neoadjuvant systemic treatment in HCC. Finally, we review recent developments in the adjuvant and neoadjuvant settings for BTC. While promising data exist across these settings, uncertainties remain regarding whether these strategies will become standard of care in the coming years.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Edeline J, Kuang M, Reig M, et al. Integrating systemic therapy in the earlier stages of liver cancer. J Hepatol. 2026. PMID: 42744525. doi:10.1016/j.jhep.2026.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。